Role of leucine-rich α-2-glycoprotein in Taiwanese patients with inflammatory bowel disease as a predictive biomarker for endoscopic activity

Figure 4 Diagnostic probability of the combination of blood-based biomarkers, with or without leucine-rich α-2-glycoprotein, in detecting active endoscopic disease in Crohn’s disease and in the Crohn’s disease with low C-reactive protein subgroup. A: C-reactive protein (CRP) + hemoglobin (Hb) with or without leucine-rich α-2-glycoprotein (LRG) comparison in all Crohn’s disease (CD) patients; B: CRP + Hb + albumin with or without LRG comparison in all CD patients; C: CRP + Hb with or without LRG comparison in CD patients with low CRP (CRP < 0.08 mg/dL); D: CRP + Hb + albumin with or without LRG comparison in CD patients with low CRP (CRP < 0.08 mg/dL). CD: Crohn’s disease; CRP: C-reactive protein; LRG: Leucine-rich α-2-glycoprotein; Hb: Hemoglobin; AUC: Area under the curve; Alb: Albumin; AUROC: Area under the receiver operating characteristic curve.